ArticleCancers2022

Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma.

Lingzhi Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.